Dr Kaiser's reserch group investigates how host immune and metabolic responses drive tuberculosis (TB) progression and its debilitating complication, cachexia, following Mycobacterium tuberculosis (Mtb) infection. Using integrated molecular biology, immunology, and bioinformatics approaches, we aim to define the critical host-pathogen interactions underlying these processes. This work seeks to identify novel host-directed therapeutic strategies to combat TB and its associated cachexia.